Gallbladder disease : Significant weight loss associated with GLP-1 therapies may increase the risk of gallstones
Jeff Atlas, PA-C, whose background in orthopaedics informs a structured, goal-driven approach to treatment
While in use, they saturate those receptors particularly in the brain and stomach mimicking the effects of endogenous GLP-1 at sky-high, sustained levels
In SURMOUNT-OSA 1, which included patients who were not using PAP therapy, 43% of participants on the highest dose met the criteria for disease resolution
Given the complexity of the clinical effects exhibited by DPP-4 inhibitors in diabetes, it may not be entirely informative to refer to them solely as incretin-based drugs
48,49 Investigating GLP-1 agonism could provide critical insights into restoring metabolic homeostasis in aging tissues and may expand the therapeutic scope of GLP-1 RAs beyond their current indications